Osteoporosis
Conditions
Interventions
Osteoporosis with anti-osteoporosis treatment group:NA
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=45 years; 2.Meet the diagnostic criteria for osteoporosis as outlined in Guidelines for the diagnosis and treatment of primary osteoporosis(2022)from Chinese Society of Osteoporosis and Bone Mineral Research; 3.Patients have received regular anti-osteoporosis drug treatment for at least 1 year, which includes one of the following regimens: oral alendronate 70 mg once weekly for at least 12 months, or intravenous infusion of zoledronic acid 5 mg (once per year) at least once, or subcutaneous injection of denosumab 60 mg (once every six months) at least twice, or subcutaneous injection of bone formation-promoting drug teriparatide 20 µg daily for at least 12 months; 4.The patient's medical history, bone density, and laboratory data are relatively complete upon review by the researcher; 5.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with unstable secondary osteoporosis during treatment, such as those receiving stable doses of corticosteroids or patients with stable breast cancer undergoing endocrine therapy; 2.Patients with psychiatric disorders or those with cognitive dysfunction; 3.Poor medication adherence, with alendronate and teriparatide adherence =60 days in receiving two doses of denosumab treatment; 4.Patients with a history of allergies to or contraindications for the drugs used in the study; 5.Patients with significant liver or kidney dysfunction, defined as AST or ALT >= 2.5 times the upper limit of normal, or eGFR <= 60 ml/min*1.73m²; 6.Patients with a current history of cancer, or severe organ diseases such as heart, brain, or kidney conditions, except for those with stable differentiated thyroid cancer or early-stage breast cancer after surgery; 7.Patients whom the researcher deems unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density;Key regulatory genes of anti-osteoporosis drug metabolism; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone metabolism markers TRACP and P1NP; | — |
Countries
China
Contacts
Public ContactMa Xiao
China-Japan Friendship Hospital
Outcome results
None listed